Radiosynoviorthesis  ||| S:0 E:20 ||| NNP
in  ||| S:20 E:23 ||| IN
children  ||| S:23 E:32 ||| NNS
with  ||| S:32 E:37 ||| IN
haemophilia  ||| S:37 E:49 ||| JJ
Recurrent  ||| S:49 E:59 ||| JJ
bleeding  ||| S:59 E:68 ||| NN
into  ||| S:68 E:73 ||| IN
joints  ||| S:73 E:80 ||| NN
represents  ||| S:80 E:91 ||| VBZ
the  ||| S:91 E:95 ||| DT
clinical  ||| S:95 E:104 ||| JJ
hallmark  ||| S:104 E:113 ||| NN
of  ||| S:113 E:116 ||| IN
haemophilia  ||| S:116 E:128 ||| NN
and ||| S:128 E:131 ||| CC
,  ||| S:131 E:133 ||| ,
if  ||| S:133 E:136 ||| IN
not  ||| S:136 E:140 ||| RB
adequately  ||| S:140 E:151 ||| RB
treated ||| S:151 E:158 ||| VBN
,  ||| S:158 E:160 ||| ,
it  ||| S:160 E:163 ||| PRP
may  ||| S:163 E:167 ||| MD
cause  ||| S:167 E:173 ||| VB
chronic  ||| S:173 E:181 ||| JJ
synovitis  ||| S:181 E:191 ||| NN
and  ||| S:191 E:195 ||| CC
degenerative  ||| S:195 E:208 ||| JJ
arthropathy ||| S:208 E:219 ||| NN
.  ||| S:219 E:221 ||| .
The  ||| S:221 E:225 ||| DT
first  ||| S:225 E:231 ||| JJ
treatment  ||| S:231 E:241 ||| NN
option  ||| S:241 E:248 ||| NN
of  ||| S:248 E:251 ||| IN
recurrent  ||| S:251 E:261 ||| JJ
haemarthroses  ||| S:261 E:275 ||| NN
and ||| S:275 E:278 ||| CC
/ ||| S:278 E:279 ||| NNP
or  ||| S:279 E:282 ||| CC
chronic  ||| S:282 E:290 ||| JJ
synovitis  ||| S:290 E:300 ||| NN
is  ||| S:300 E:303 ||| VBZ
represented  ||| S:303 E:315 ||| VBN
by  ||| S:315 E:318 ||| IN
synoviorthesis ||| S:318 E:332 ||| NN
,  ||| S:332 E:334 ||| ,
both  ||| S:334 E:339 ||| DT
chemical  ||| S:339 E:348 ||| NN
and  ||| S:348 E:352 ||| CC
radioisotopic ||| S:352 E:365 ||| NN
,  ||| S:365 E:367 ||| ,
with  ||| S:367 E:372 ||| IN
a  ||| S:372 E:374 ||| DT
success  ||| S:374 E:382 ||| NN
rate  ||| S:382 E:387 ||| NN
of  ||| S:387 E:390 ||| IN
approximately  ||| S:390 E:404 ||| RB
80 ||| S:404 E:406 ||| CD
%  ||| S:406 E:408 ||| NN
for  ||| S:408 E:412 ||| IN
both ||| S:412 E:416 ||| DT
.  ||| S:416 E:418 ||| .
However ||| S:418 E:425 ||| RB
,  ||| S:425 E:427 ||| ,
radioisotopic  ||| S:427 E:441 ||| JJ
synoviorthesis  ||| S:441 E:456 ||| NN
should  ||| S:456 E:463 ||| MD
be  ||| S:463 E:466 ||| VB
preferred  ||| S:466 E:476 ||| VBN
because  ||| S:476 E:484 ||| IN
it  ||| S:484 E:487 ||| PRP
makes  ||| S:487 E:493 ||| VBZ
it  ||| S:493 E:496 ||| PRP
possible  ||| S:496 E:505 ||| JJ
to  ||| S:505 E:508 ||| TO
obtain  ||| S:508 E:515 ||| VB
complete  ||| S:515 E:524 ||| JJ
synovial  ||| S:524 E:533 ||| NNS
fibrosis  ||| S:533 E:542 ||| VBP
usually  ||| S:542 E:550 ||| RB
in  ||| S:550 E:553 ||| IN
one  ||| S:553 E:557 ||| CD
session ||| S:557 E:564 ||| NN
,  ||| S:564 E:566 ||| ,
without  ||| S:566 E:574 ||| IN
the  ||| S:574 E:578 ||| DT
need  ||| S:578 E:583 ||| NN
for  ||| S:583 E:587 ||| IN
repeated  ||| S:587 E:596 ||| JJ
injections ||| S:596 E:606 ||| NNS
,  ||| S:606 E:608 ||| ,
thus  ||| S:608 E:613 ||| RB
reducing  ||| S:613 E:622 ||| VBG
the  ||| S:622 E:626 ||| DT
risk  ||| S:626 E:631 ||| NN
of  ||| S:631 E:634 ||| IN
bleeding  ||| S:634 E:643 ||| VBG
complications  ||| S:643 E:657 ||| NNS
and  ||| S:657 E:661 ||| CC
concentrate  ||| S:661 E:673 ||| VB
consumption ||| S:673 E:684 ||| NN
.  ||| S:684 E:686 ||| .
For  ||| S:686 E:690 ||| IN
all  ||| S:690 E:694 ||| PDT
these  ||| S:694 E:700 ||| DT
reasons  ||| S:700 E:708 ||| NNS
this  ||| S:708 E:713 ||| DT
procedure  ||| S:713 E:723 ||| NN
should  ||| S:723 E:730 ||| MD
be  ||| S:730 E:733 ||| VB
implemented  ||| S:733 E:745 ||| VBN
and  ||| S:745 E:749 ||| CC
supported ||| S:749 E:758 ||| VBN
,  ||| S:758 E:760 ||| ,
particularly  ||| S:760 E:773 ||| RB
in  ||| S:773 E:776 ||| IN
developing  ||| S:776 E:787 ||| VBG
countries ||| S:787 E:796 ||| NNS
.  ||| S:796 E:798 ||| .
